Company intelligence / Profile preview

ENTvantage Dx

Austin, Texas, United Statesentvantagedx.com ↗

Ownership: Private
Development stage: Other

Overview

ENTvantage Dx has developed Sinu-Test®, a rapid point-of-care diagnostic for distinguishing bacterial from viral sinus infections. The product aims to reduce unnecessary antibiotic prescriptions by enabling accurate diagnosis within 20 minutes. Clinical trials are ongoing in the U.S., and the company plans regulatory submissions and commercial scale-up activities. The Sinu-Test® has issued patents in multiple regions and established reimbursement pathways.

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic test kit (in-vitro diagnostic)
Industry: Protein Biomarker Diagnostics

Partnerships

University of North Texas Health Science CenterAcceleration Lab Technology Commercialization Program

Beyond the preview

Go deeper on ENTvantage Dx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENTvantage Dx.

Explore the full profile